MedTrace Logo

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

NCT05326906 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-05-16

No results posted yet for this study

Summary

Immune checkpoint inhibitors have revolutionized lung cancer (LC) treatment, demonstrating a significant improvement in overall survival. However high-grade immune-related adverse events (irAEs) may result in harmful and serious clinical outcomes, even death. Immune-related hepatitis (IRH) is a potentially serious complication of checkpoint blockade, with an incidence of 5%-10% for ICIs monotherapy, including 1%-2% with grade 3 or higher. Therefore, it is particularly important to explore new and better prognostic and predictive biomarkers for IRH.

Conditions

Interventions

DRUG

PD-1/PD-L1 inhibitors

PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2021-05-01
Completion
2022-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05326906 on ClinicalTrials.gov